Successful Treatment of Drooling in Children with Neurological Disorders with Botulinum Toxin A or B

被引:54
作者
Wilken, B. [1 ]
Aslami, B. [1 ]
Backes, H. [1 ]
机构
[1] Klinikum Kassel, Dept Pediat Neurol, D-34125 Kassel, Germany
关键词
botulinum toxin A; botulinum toxin B; drooling; sialorrhea; salivary glands;
D O I
10.1055/s-0028-1112115
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drooling is a common and severe problem in children with neurological disorders and is caused by a disturbed coordination of orofacial and palatolingual muscles. Botulinum toxin could be a successful option to reduce excessive sialorrhea in children with neurological disorders. In 30 children with cerebral palsy or neurodegenerative disorder we injected under ultrasound guidance either botulinum toxin A or botulinum toxin B into the parotid and submandibular glands on both sides. All injections were well tolerated without general anaesthesia. Drooling severity at baseline and reduction of sialorrhea during treatment was measured using a parent's questionnaire and rated using the Teachers Drooling Scale (TDS). Reduction of sialorrhea was achieved two weeks after injection, with a positive effect lasting about three to four months in most children. 83 % showed a good response to botulinum toxin after first injection, but only in 50% treatment was continued. We found no significant differences between botulinum toxin A or B. Side effects were observed in 5 children with viscous saliva and in one child a unilateral parotitis was observed. Treatment of drooling with botulinum toxin into the salivary glands is a safe and easy therapeutic option for children with neurological disorders to improve life quality.
引用
收藏
页码:200 / 204
页数:5
相关论文
共 27 条
[1]   Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy [J].
Banerjee, K. J. ;
Glasson, C. ;
O'Flaherty, S. J. .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2006, 48 (11) :883-887
[2]   Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands [J].
Berweck, Steffen ;
Schroeder, A. Sebastian ;
Lee, Seung-Hee ;
Bigalke, Hans ;
Heinen, Florian .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2007, 49 (01) :62-64
[3]   Glycopyrrolate treatment of chronic drooling [J].
Blasco, PA ;
Stansbury, JCK .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1996, 150 (09) :932-935
[4]  
CAMPBRUNO JA, 1989, DEV MED CHILD NEUROL, V31, P309
[5]   Management of drooling in individuals with neurodisability: a surgical experience [J].
Crysdale, WS ;
Raveh, E ;
McCann, C ;
Roske, L ;
Kotler, A .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2001, 43 (06) :379-383
[6]   Clinical use of non-A botulinum toxins: Botulinum toxin type B [J].
Dressler, Dirk ;
Eleopra, Roberto .
NEUROTOXICITY RESEARCH, 2006, 9 (2-3) :121-125
[7]   Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies [J].
Ellies, M ;
Laskawi, R ;
Rohrbach-Volland, S ;
Arglebe, C .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2003, 61 (04) :454-457
[8]   Successful management of drooling with botulinum toxin A in neurologically disabled children [J].
Ellies, M ;
Rohrbach-Volland, S ;
Arglebe, C ;
Wilken, B ;
Laskawi, R ;
Hanefeld, F .
NEUROPEDIATRICS, 2002, 33 (06) :327-330
[9]   Visual side-effects from transdermal scopolamine (hyoscine) [J].
Firth, AY ;
Walker, K .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2006, 48 (02) :137-138
[10]  
FREDERICK FJ, 1982, J OTOLARYNGOL, V11, P289